GURUFOCUS.COM » STOCK LIST » Europe » Germany » HAM » Biogen Inc (HAM:IDP) » Definitions » Debt-to-EBITDA
Switch to:

Biogen (HAM:IDP) Debt-to-EBITDA

: 1.98 (As of Dec. 2022)
View and export this data going back to 2001. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €0 Mil. Biogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €6,244 Mil. Biogen's annualized EBITDA for the quarter that ended in Dec. 2022 was €3,148 Mil. Biogen's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was 1.98.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Biogen's Debt-to-EBITDA or its related term are showing as below:

HAM:IDP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13   Med: 1.01   Max: 2.64
Current: 1.5

During the past 13 years, the highest Debt-to-EBITDA Ratio of Biogen was 2.64. The lowest was 0.13. And the median was 1.01.

HAM:IDP's Debt-to-EBITDA is ranked better than
53.94% of 634 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs HAM:IDP: 1.50

Biogen Debt-to-EBITDA Historical Data

The historical data trend for Biogen's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.82 1.37 2.64 1.52

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 3.41 1.28 1.07 1.98

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biogen's Debt-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the Debt-to-EBITDA's extreme value range as defined by GuruFocus.



Biogen Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biogen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 6243.61599999) / 4112.8191999934
=1.52

Biogen's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 6243.61599999) / 3147.673599995
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.


Biogen  (HAM:IDP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Biogen Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biogen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (HAM:IDP) Headlines

No Headlines